A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of PF-06342674 (M168) In Adults With Type 1 Diabetes

Trial Profile

A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of PF-06342674 (M168) In Adults With Type 1 Diabetes

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs PF 6342674 (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 02 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 02 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Aug 2016.
    • 02 May 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Aug 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top